This week, the European Medicines Agency (EMA) announced that it will scale back and even fully suspend a number of its activities in order to cope with Brexit-related pressures, and as the possibility grows stronger that the United Kingdom and the European Union may not reach a trade agreement, some drug makers have begun to stockpile key medicines to help guard against a supply disruption.
This week, the European Medicines Agency (EMA) announced that it will scale back and even fully suspend a number of its activities in order to cope with Brexit-related pressures.
The agency says that, through 2019, it will reduce or halt its work on international collaboration (including taking only a “reactive role” on the harmonization of global medicine regulation), the development and revision of guidelines, and the launch of new procedures for clinical data publication, among other activities.
These cuts come in addition to rollbacks made in 2017 as part of an initial Brexit preparedness effort. The programs suspended last year include the development of a European Medicines Web Portal, contribution to an electronic submission portal to allow for online filing of documents related to drug applications, and participation in benchmarking EU member states’ regulatory agencies.
The agency says that the cuts to activities are the result of losing more staff than it initially anticipated in preparing for its move from London, United Kingdom to Amsterdam, Netherlands. While the EMA initially said that it could expect to retain approximately 65% of its staff overall in the move, in this week’s announcement, it indicated that it now expects to lose approximately 30% of its workers in the near term, and that it has “a high degree of uncertainty regarding mid-term staff retention.” Dutch employment laws appear to be partly to blame for the loss of workers; more than 100 contract staff will no longer be permitted to work for the EMA after its move.
Meanwhile, as the possibility grows stronger that the United Kingdom and the European Union may not reach a trade agreement, some drug makers have begun to stockpile key medicines to help guard against a supply disruption. Drug makers Sanofi and Novartis have confirmed to the BBC that they are holding extra units of their products so that patients will not have to go without their medication in the event of a “no-deal” Brexit and a disruption to trade.
The chair of the United Kingdom’s Medicines and Healthcare Products Regulatory Agency, Sir Michael Rawlins, has spoken candidly about the fact that supply chain disruption could leave people with diabetes without access to insulin. Speaking to The Pharmaceutical Journal, Rawlins highlighted the fact that the United Kingdom manufactures no insulin itself, and relies of the European Union for its supply. “We can’t suddenly start manufacturing insulin,” he noted.
Currently, 45 million patient-ready packages of medicines are supplied to the European Union from the United Kingdom each month, and the United Kingdom receives 37 million packages each month from the European Union.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.